AIDS Drug Assistance Program (ADAP) Formulary Overview
The CARE Act gives States the authority to determine which drugs to include on the formulary for their AIDS Drug Assistance Program (ADAP), provided that the drugs have been approved by the Food and Drug Administration (FDA) to treat HIV disease, including measures for the prevention and treatment of opportunistic diseases. Most ADAPs provide access to drugs used to treat or prevent opportunistic diseases that develop in later stages of illness, either directly through the ADAP formulary or in cooperation with Title II-funded consortia. As of FY 2002, all but 3 States report more than 25 drugs on their ADAP formulary, with Massachussetts and New Jersey using a combination of State and Federal funds to move to an open drug formulary (i.e., inclusion of all medications related to the care and treatment of HIV/AIDS).
In the past few years, States have focused increased attention on their formularies due to the emergence of new and effective, though costly, combination antiretroviral drug treatments. This combination therapy, or "drug cocktail" typically includes one protease inhibitor with two or more antiretroviral drugs to significantly reduce the amount of virus in the body (called the viral load). Combination therapy has the potential to improve a patient's health status, life expectancy, and quality of life. However, the cost of providing combination therapy is currently about $10,000 to $12,000 per person per year, excluding other needed medicine or primary care costs.
This article was provided by U.S. Health Resources and Services Administration.